Polycythemia epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
| Line 32: | Line 32: | ||
*In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females. <ref name="urlPolycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs">{{cite web |url=https://www.globenewswire.com/news-release/2020/07/15/2062391/0/en/Polycythemia-Vera-PV-Trends-Epidemiology-2017-2030-KOL-Views-and-Unmet-Needs.html |title=Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs |format= |work= |accessdate=}}</ref> | *In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females. <ref name="urlPolycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs">{{cite web |url=https://www.globenewswire.com/news-release/2020/07/15/2062391/0/en/Polycythemia-Vera-PV-Trends-Epidemiology-2017-2030-KOL-Views-and-Unmet-Needs.html |title=Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs |format= |work= |accessdate=}}</ref> | ||
===Region=== | ===Region=== | ||
* | *Incidence of cases is higher in the United States and Europe than in Japan. <ref name="pmid32491592">{{cite journal |vauthors=Lu X, Chang R |title= |journal= |volume= |issue= |pages= |date= |pmid=32491592 |doi= |url=}}</ref>. <ref name="pmid16673273">{{cite journal |vauthors=Johansson P |title=Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia |journal=Semin Thromb Hemost |volume=32 |issue=3 |pages=171–3 |date=April 2006 |pmid=16673273 |doi=10.1055/s-2006-939430 |url=}}</ref> | ||
===Developed Countries=== | ===Developed Countries=== | ||
Revision as of 02:58, 9 December 2020
|
Polycythemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Polycythemia epidemiology and demographics |
|
Risk calculators and risk factors for Polycythemia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]
Overview
Epidemiology and Demographics
Incidence
- The incidence of polycythemia vera is approximately 1.9 per 100,000 individuals in the United States.
- Taking into account all races and ethnicities, the incidence is approximately 2.8 per 100,000 males and 1.3 per 100,000 in females. [1]
Prevalence
- The prevalence of polycythemia vera in the 7 MM countries was 283,442 in 2017.
- Prevalence of polycythemia vera was the highest in the US in 2017 at 157,290, out of which 62,916 cases were asymptomatic and 94,374 were symptomatic. [2]
- 22 cases per 100,000 people. [1]
Case-fatality rate/Mortality rate
- 4 year mortality rate is >10%.
- On an average patients lived with the disease for 8.6 years (mean), the cases that were fatal were approximately 77.1 years of age on average.
- Comorbidities such as cardiovascular diseases, other blood and lymphatic disorders, vascular disorders, mass occupying lesions in the thorax, respiratory system, infections, etc accounted for more deaths more often.
- Thrombotic complications were the most common cause of death followed by hematologic malignancy. [3]
Age
- It has been noted that PV is more common in the age group >75. [2]
- Median age of diagnosis is 60. [4]
Race
- Jews of Eastern European descent have a higher number of cases as compared to other Europeans or Asians. [1]
Gender
- Generally, there is no sex predeliction.[4]
- In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females. [2]
Region
Developed Countries
Developing Countries
References
- ↑ 1.0 1.1 1.2 "www.lls.org" (PDF).
- ↑ 2.0 2.1 2.2 "Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs".
- ↑ "www.hematologyadvisor.com".
- ↑ 4.0 4.1 4.2 Lu X, Chang R. PMID 32491592 Check
|pmid=value (help). Missing or empty|title=(help) - ↑ Johansson P (April 2006). "Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia". Semin Thromb Hemost. 32 (3): 171–3. doi:10.1055/s-2006-939430. PMID 16673273.